Media stories about Ekso Bionics (NASDAQ:EKSO) have been trending somewhat positive recently, according to Accern Sentiment Analysis. The research group rates the sentiment of media coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Ekso Bionics earned a news sentiment score of 0.09 on Accern’s scale. Accern also assigned news stories about the company an impact score of 45.9676522312961 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.

Here are some of the news headlines that may have effected Accern Sentiment Analysis’s rankings:

A number of research analysts have commented on EKSO shares. ValuEngine upgraded shares of Ekso Bionics from a “hold” rating to a “buy” rating in a research note on Thursday, July 12th. Zacks Investment Research upgraded shares of Ekso Bionics from a “hold” rating to a “buy” rating and set a $2.00 price objective on the stock in a research note on Thursday, July 19th.

NASDAQ EKSO traded down $0.12 during trading hours on Friday, reaching $2.63. 1,624,544 shares of the company traded hands, compared to its average volume of 1,215,188. Ekso Bionics has a 12 month low of $1.02 and a 12 month high of $4.77. The company has a debt-to-equity ratio of 0.49, a current ratio of 2.17 and a quick ratio of 2.50. The company has a market capitalization of $167.29 million, a price-to-earnings ratio of -2.96 and a beta of -0.69.

Ekso Bionics (NASDAQ:EKSO) last posted its quarterly earnings data on Tuesday, August 7th. The company reported ($0.13) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.11) by ($0.02). Ekso Bionics had a negative net margin of 327.12% and a negative return on equity of 169.75%. The company had revenue of $2.97 million for the quarter, compared to the consensus estimate of $3.03 million. analysts anticipate that Ekso Bionics will post -0.44 EPS for the current year.

In other Ekso Bionics news, Director Steven Sherman purchased 200,000 shares of Ekso Bionics stock in a transaction dated Wednesday, May 23rd. The shares were bought at an average cost of $1.51 per share, for a total transaction of $302,000.00. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 35.45% of the company’s stock.

Ekso Bionics Company Profile

Ekso Bionics Holdings, Inc designs, develops, and sells exoskeletons for use in the healthcare, industrial, and military markets in North America, Europe, the Middle East, and Africa. The company operates through Medical Devices, Industrial Sales, and Engineering Services segments. It primarily offers Ekso GT, a bionic suit that provides the ability to stand and walk over ground with a reciprocal gait using a cane, crutches, or a walker to individuals with spinal cord injuries, hemiplegia due to stroke, and lower limb paralysis or weakness.

Further Reading: Growth Stocks

Insider Buying and Selling by Quarter for Ekso Bionics (NASDAQ:EKSO)

Receive News & Ratings for Ekso Bionics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ekso Bionics and related companies with MarketBeat.com's FREE daily email newsletter.